This report provides a snapshot of key aspects of behavioral health, serious mental illness, suicidal thoughts, and mental illness, substance use disorders, or both. The information is based on selected determinants of health, including race and ethnicity, income level, geography, and health insurance status.

This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.

This guide explains how to use extended-release injectable naltrexone as part of medication-assisted treatment (MAT) for opioid use disorder. It covers assessing patients, initiating MAT, monitoring progress, and deciding when to end treatment.

This brochure informs patients about buprenorphine and medication-assisted treatment for opioid use disorder. It describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.

This series of four fact sheets emphasizes the importance of continuing a mother's treatment for opioid use disorder (OUD) throughout pregnancy. The series includes information on OUD and pregnancy, OUD treatment, neonatal abstinence syndrome, and considerations to address before hospital discharge.

This brochure describes the use of methadone in medication-assisted treatment of heroin and other opioids, including narcotic pain medicines. It describes how to use methadone safely, the dangers of methadone overdose, and life-threatening methadone side effects.